Astellas Pharma (OTCMKTS:ALPMY) Shares Gap Up – What’s Next?

Astellas Pharma Inc. (OTCMKTS:ALPMY) gapped up before the market opened on Monday . The stock had previously closed at $14.56, but opened at $15.4168. Astellas Pharma shares last traded at $14.85, with a volume of 11,098 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Zacks Research lowered Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy”.

Astellas Pharma Stock Up 1.6%

The firm has a market capitalization of $26.76 billion, a P/E ratio of 11.26 and a beta of 0.08. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.93 and a current ratio of 1.20. The business’s fifty day moving average price is $14.19 and its two-hundred day moving average price is $14.57.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Japan-based pharmaceutical company that discovers, develops and commercializes prescription medicines for serious and unmet medical needs. Its research and commercial activities focus on areas including oncology, urology, immunology, neuromuscular diseases, ophthalmology and other specialty conditions.

The company’s portfolio includes treatments such as XTANDI for certain prostate cancers, XOSPATA for acute myeloid leukemia, MYRBETRIQ for overactive bladder and VEOZAH for menopausal hot flashes.